Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Hanna J. Johnsson
Based on 2 articles published since 2009
(Why 2 articles?)
||||

Between 2009 and 2019, Hanna Johnsson wrote the following 2 articles about Spinal Diseases.
 
+ Citations + Abstracts
1 Review Interleukin-12 and interleukin-23 inhibition in psoriatic arthritis. 2015

Johnsson, Hanna J / McInnes, Iain B. ·Institute of Infection, Immunity and Inflammation, University of Glasgow, UK. hanna.johnsson@glasgow.ac.uk. · Institute of Infection, Immunity and Inflammation, University of Glasgow, UK. ·Clin Exp Rheumatol · Pubmed #26471946.

ABSTRACT: The cytokines interleukin (IL)-12 and interleukin (IL)-23 have been implicated variously in the pathogenesis of psoriasis and psoriatic arthritis (PsA). By corollary, the IL-12/23 inhibitor, Ustekinumab has been developed as an approved therapeutic for the skin and musculoskeletal syndrome of psoriasis / PsA. This review describes briefly the role of IL-12 and IL-23 in the pathophysiology of psoriatic arthritis and evaluates trial data that support its clinical use in psoriasis and different manifestations of psoriatic arthritis. The next steps towards targeting this pathway also are discussed.

2 Review Cardiovascular and metabolic risks in psoriasis and psoriatic arthritis: pragmatic clinical management based on available evidence. 2012

Johnsson, Hanna / McInnes, Iain B / Sattar, Naveed. ·Institute of Cardiovascular and Medical Sciences, BHF Glasgow Cardiovascular Research Centre, University of Glasgow, UK. h.johnsson@doctors.org.uk ·Ann Rheum Dis · Pubmed #22294632.

ABSTRACT: Several studies suggest that patients with psoriasis and, in particular, psoriatic arthritis (PsA) are at increased risk of cardiovascular disease. These patients are also more likely to be obese and to have diabetes and fatty liver disease. This article discusses the association between psoriasis and PsA and cardiometabolic disorders, emphasising the need for better consideration of simple lifestyle interventions. It also highlights areas for future research and proposes a simple and pragmatic test portfolio to screen for cardiovascular risk and metabolic disorders in patients at higher risk.